A number of Fred Hutchinson Cancer Research Center discoveries have been translated into new businesses and products that create jobs, advance health and generate financial returns for inventors, partners and the Center’s research. Some of our success stories include:
Immunex was founded in 1981 in Seattle by former Center scientists Drs. Christopher Henney and Steve Gillis. Dedicated to developing immune system science to protect human health, the company marketed innovative products to treat cancer and rheumatoid arthritis, and also conducted clinical research in the areas of autoimmune disorders and cardiovascular and infectious diseases. Immunex was acquired by Amgen.
Genetic Systems, founded in 1980 in Seattle, manufactured virus and infectious disease diagnostic blood tests as well as related instrument and software systems. Genetic Systems was founded in part on technology licensed from Fred Hutch. Genetic Systems became a public company through an IPO in 1985 and was subsequently acquired by Bristol-Myers Squibb.
Targeted Genetics was founded in 1992 in Seattle as a spin-off of Immunex with technologies licensed from Fred Hutch. The company is focused on the discovery, development and commercialization of cutting-edge gene and cell therapy products for both acquired and inherited diseases. Targeted Genetics became a public company in 1994.
Rosetta Inpharmatics LLC
Rosetta Inpharmatics was co-founded by Fred Hutch in Seattle in 1996. Rosetta provides services for drug discovery and development using biochip or array, technology and advanced informatics technologies. The company is focused on the identification of therapeutic compounds for the treatment of cancer and immunological diseases. Rosetta became a public company in 2000. Rosetta Inpharmatics was subsequently acquired by Merck & Co.
Adeza Biomedical Corporation
Adeza, located in Sunnyvale, Calif., is developing new diagnostic and therapeutic products for the women’s health market. Founded in 1985 as Aspen Diagnostics, Adeza’s first product is a novel FDA-approved diagnostic for early identification of women at risk for pre-term delivery. The product arose from research at Fred Hutch. Adeza became a public company in 2004 and was acquired by Cytyc Corp. in 2007.
Argus Genetics was established in 2004 to serve as conduit between Fred Hutch and Mars, Inc. In 2007 Mars, using technology developed at Fred Hutch, launched a simple test to determine the genetic profile of a dog.